Methodological challenges in the evaluation of prognostic factors in breast cancer

Breast Cancer Research and Treatment

Volumn 52, Issue 1-3, 1998, Pages 289-303

  Altman, Douglas G ^a   Lyman, Gary H ^b,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Continuous variables; Cutpoints; Interaction analysis; Meta analysis; Model validation; Multiple regression analysis; Prognostic studies; Sample size; Study design; Tests of predictiveness

Indexed keywords

BREAST CANCER; HUMAN; MEDICAL RESEARCH; METHODOLOGY; MULTIPLE REGRESSION; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SAMPLE;

EID: 0032445262     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006193704132     Document Type: Review

References (61)

1. McGuire WL: Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst 83:154-155, 1991
2. Gasparini G, Pozza F, Harris AL: Evaluating the potential usefulness of new prognostic and predictive indicators in node negative breast cancer patients. J Natl Cancer Inst 85:1206-1219, 1993
3. Clark GM, Wenger CR, Beardslee S, et al: How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer. Cancer 71:2157-2162, 1993
4. Simon R, Altman DG: Statistical aspects of prognostic factor studies in oncology. Br J Cancer 6:979-985, 1994
5. Gray-Donald K, Kramer MS: Causality inference in observational vs. experimental studies. An empirical comparison. Am J Epidemiol 127:885-892, 1988
6. Tukey JW: Some thoughts on clinical trials, especially problems of multiplicity. Science 198:679-684, 1977
7. Fayers PM, Machin D: Sample size: how many patients are necessary? Br J Cancer 72:1-9, 1995
8. Machin D, Campbell MJ, Fayers PM, Pinol APY: Sample Size Tables for Clinical Studies, 2nd edition. Blackwell, Oxford, 1997
9. Harrell FE, Lee KL, Matchar DB, Reichert TA: Regression models for prognostic prediction: advantages, problems, and suggested solutions. Cancer Treat Rep 69:1071-1077, 1985
10. Peduzzi P, Concato J, Feinstein AR, Holford TR: The importance of events per independent variable (EPV) in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 48:1503-1510, 1995
11. Altman DG, De Stavola BL, Love SB, Stepniewska KA: Review of survival analyses published in cancer journals. Br J Cancer 72:511-518, 1995
12. Axelsson K, Ljung B-ME, Moore DH, et al: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 87:997-1008, 1995
13. Press MF, Hung G, Godolphin W, Slamon DJ: Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohisto-chemical studies of oncogene expression. Cancer Res 54:2771-2777, 1994
14. Romero H, Schneider J: Different detection rates of HER-2/NEU overexpression in ovarian carcinoma using two different commercially available detection kits. Eur J Cancer 31A:1020-1021, 1995
15. Molino A, Micciolo R, Turazza M, et al: Prognostic significance of estrogen receptors in 405 primary breast cancers: a comparison of immunohistochemical and biochemical methods. Breast Cancer Res Treat 345:241-249, 1997
16. Bland JM, Altman DG: Statistical methods for comparing two methods of measurement. Lancet i:307-310, 1986
17. Cox DR: Regression models and life-tables. J R Stat Soc B 34:187-220, 1972
18. Fielding LP, Fenoglio-Preiser CM, Freedman LS: The future of prognostic factors in outcome prediction for patients with cancer. Cancer 70:2367-2377, 1992
19. Chen C-H, George SL: The bootstrap, and identification of prognostic factors via Cox's proportional hazards regression model. Stat Med 4:39-46, 1985
20. Altman DG, Andersen PK: Bootstrap investigation of the stability of a Cox regression model. Stat Med 8:771-783, 1989
21. Sauerbrei W, Schumacher M: A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med 11:2093-2109, 1992
22. Schumacher M, Höllander, N, Sauerbrei W: Resampling and cross-validation techniques: a tool to reduce bias caused by model building? Stat Med 16:2813-2827, 1997
23. Gamel JW, McCurdy JB, McLean IW: A comparison of prognostic covariates for uveal melanoma. Invest Ophthalmol Vis Sci 33:1919-1922, 1992
24. Jenks S, Volkers N: Razors and refrigerators and reindeer - oh my. J Natl Cancer Inst 84:1863, 1992
25. Peters JM, Preston-Martin S, London SJ, et al: Processed meats and risk of childhood leukemia (California, USA). Cancer Causes Control 5:195-202, 1994
26. Wyatt JC, Altman DG: Prognostic models: clinically useful or quickly forgotten? Br Med J 311:1539-1541, 1995
27. Altman DG, Royston P: What do we mean by validating a prognostic model? Stat Med, in press
28. Vach W: Some issues in estimating the effect of prognostic factors from incomplete covariate information. Stat Med 16:57-72, 1997
29. Sagman U, Maki E, Evans WK, et al: Small-cell carcinoma of the lung: derivation of a prognostic staging system. J Clin Oncol 9:1639-1649, 1991
30. Thor A, Benz C, Moore D, et al: Stress response protein (srp-27) determination in primary human breast carcinomas: clinical, histologic, and prognostic correlations. J Natl Cancer Inst 83:170-178, 1991
31. Hart A, Wyatt J: Evaluating black boxes as medical decision-aids: issues arising from a study of neural networks. Med Informatics 15:229-236, 1990
32. Ohno-Machado L: A comparison of Cox proportional hazards and artificial network models for medical prognosis. Comput Biol Med 27:55-65, 1997
33. Schwarzer G, Vach W, Schumacher M: On the misuses of artificial neural networks for prognostic factor and diagnostic classification in oncology. University of Freiburg Technical Report No. 46, 1997
34. Morgan TM, Elashoff RM: Effect of categorizing a continuous covariate on the comparison of survival time. J Am Stat Assoc 81:917-921, 1986
35. Hilsenbeck SG, Clark GM, McGuire WL: Why do so many prognostic factors fail to pan out? Breast Cancer Res Treat 22:197-206, 1992
36. Altman DG, Lausen B, Sauerbrei W, Schumacher M: Dangers of using 'optimal' cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86:829-835, 1994
37. Altman DG: Suboptimal analysis using 'optimal' cutpoints. Br J Cancer 78:556-557, 1998
38. Jänicke F, Schmitt M, Ulm K, et al: Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet 2:1049, 1989
39. Jänicke F, Schmitt M, Pache L, et al: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node negative breast cancer. Breast Cancer Res Treat 24:195-208, 1993
40. Knoop A, Andreasen PA, Andersen JA, et al: Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer 77:932-940, 1998
41. Buettner P, Garbe C, Guggenmoos-Holzmann I: Problems in defining cutoff points of continuous prognostic factors: example of tumor thickness in primary cutaneous melanoma. J Clin Epidemiol 50:1201-1210, 1997
42. Budinha M, Skrk J, Zakotnik B, et al: Prognostic value of total cathepsin B in invasive ductal carcinoma of the breast. Eur J Cancer 31A:661-664, 1995
43. Durrleman S, Simon R: Flexible regression models with cubic splines. Stat Med 8:551-561, 1989
44. Hastie T, Sleeper L, Tibshirani R: Flexible covariate effects in the proportional hazards model. Breast Cancer Res Treat 22:241-250, 1992
45. Royston P, Altman DG: Regression using fractional polynomials of continuous covariates: parsimonious parametric modelling. Appl Stat 43:429-467, 1994
46. Knorr KL, Hilsenbeck SG, Wenger CR, et al: Making the most of your prognostic factors: presenting a more accurate survival model for breast cancer patients. Breast Cancer Res Treat 22:251-262, 1992
47. Buyse M: Analysis of clinical trial outcomes: some comments on subgroup analyses. Controlled Clin Trials 10:187S-194S, 1989
48. Henry JA, McCarthy AL, Angus B, et al: Prognostic significance of the estrogen-regulated protein, cathepsin D., in breast cancer. An immunohistochemical study. Cancer 65:265-271, 1990
49. Simon R: Confidence limits for reporting results of clinical trials. Ann Intern Med 105:429-435, 1986
50. Gardner MJ, Altman DG (eds) Statistics with Confidence. British Medical Journal, London, 1989
51. Simon R: Patient subsets and variation in therapeutic efficacy. Br J Clin Pharmacol 14:473-4.82, 1982
52. Aubele N, Auer G, Falkmer U, et al: Improved prognostication in small (pT1) breast cancers by image cytometry. Breast Cancer Res Treat 36:83-91, 1995
53. Harrell FE, Lee KL, Mark DB: Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361-387, 1996
54. Haybittle JL, Blamey RW, Elston CW, et al: A prognostic index in primary breast cancer. Br J Cancer 45:361-366, 1982
55. Todd JH, Dowle C, Williams MR, et al: Confirmation of a prognostic index in primary breast cancer. Br J Cancer 56:489-492, 1987
56. Brown JM, Benson EA, Jones M: Confirmation of a long-term prognostic index in breast cancer. Breast 2:144-147, 1993
57. Stern JM, Simes RJ: Publication bias: evidence of delayed publication in a cohort study of clinical research projects. Br Med J 315:640-645, 1997
58. Ferrandina G, Scambia G, Bardelli F, et al: Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis. Br J Cancer 76:661-666, 1997
59. Fox SB, Smith K, Hollyer J, et al: The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res Treat 29:41-49, 1994
60. Rawson NSB, Peto J: An overview of prognostic factors in small cell lung cancer. Br J Cancer 61:597-604, 1990
61. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive lymphoma. N Engl J Med 329:987-994, 1993